Barter - Figure 24 - DEFINE trial Text

More recently, another CETP inhibitor, anacetrapib, has been entered in a smaller study called DEFINE that has enrolled just over 1,600 patients with CHD or coronary disease equivalents, to assess whether there is any evidence that anacetrapib shares any of the adverse effects of torcetrapib. All patients were on statin therapy sufficient to achieve an LDL cholesterol level <100 mg/dL, with that statin dose then maintained while approximately half were randomized to receive anacetrapib 100 mg/day for a 76-week trial. This trial was primarily a safety trial, so the primary endpoint was safety, but with a series of predefined secondary endpoints.

Barter P. J Clin Lipidol. 2011; 5(6).